相关实验视频
Updated: May 5, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.5K
干扰素-β治疗消除心脏型病毒,改善左心室功能,在患有心肌病毒基因组持续性和左心室功能障碍的患者
Uwe Kühl1, Matthias Pauschinger, Peter Lothar Schwimmbeck
1Department of Cardiology and Pneumology, University Hospital Benjamin-Franklin, Freie Universität Berlin, Germany. dcmkuehl@zedat.fu-berlin.de
Circulation
|May 29, 2003
概括
干扰素 (IFN) -β治疗成功清除了持续性心肌炎患者的病毒感染. 这种治疗改善了左心室功能和直径,证明了其安全性和有效性.
科学领域:
- 心脏病学 心脏病学
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 病毒感染是心肌炎的重要原因,可能导致扩张性心肌病和心脏功能障碍.
- 心肌病毒的持久性可能导致慢性左心室 (LV) 功能障碍.
研究的目的:
- 评估干扰素 (IFN) -β治疗在患有持续性病毒性心肌炎的患者中的安全性和有效性.
- 确定IFN-β治疗是否可以实现病毒清除并防止LV功能恶化.
主要方法:
- 一项II期研究涉及22名患有经过聚合酶链反应证明的肠病毒或腺病毒基因组和持续的LV功能障碍的患者.
- 患者在24周内接受皮下IFN-β (18x10^6 IU/周) 的治疗.
- 心肌炎症通过心脏内膜活检进行评估;用心声学和血管学评估LV功能.
主要成果:
- IFN-β耐受性良好,没有患者在治疗期间出现恶化.
- 在所有22名患者中观察到病毒基因组的完全清除.
- 在LV功能中发现了显著的改善:减少了LV直径 (终端透析和终端缩) 和增加了LV射出分数 (P<0.001).
结论:
- 六个月的IFN-β治疗对于患有心肌病毒持续性和LV功能障碍的患者是安全的.
- 该疗法有效地消除了所有接受治疗的患者的病毒基因组.
- IFN-β治疗导致大多数患者 (22人中15人) 改善了 LV 功能.
相关概念视频
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy IV: Restrictive Cardiomyopathy
952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Inhibitors of Viral Protein Synthesis
58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58

